Biofrontera Posts 17% Revenue Gain to $10.1M, 80% Margin and Phase 3 Win
Biofrontera reported Q1 product revenue growth of 17% to $10.1M and improved gross margin to 80%, with near-zero operating cash use versus $4.1M last year. The company lost $4.8M ($0.41/share) while securing positive Phase 3 trial results for actinic keratosis and filing a supplemental NDA.
1. Q1 Financial Performance
Biofrontera booked product revenues of $10.1 million in Q1 2026, up 17% from $8.6 million a year earlier, while gross margin climbed to 80% from 62%. The company achieved near-zero cash use in operations versus a $4.1 million burn last year, even as operating expenses rose to $14.4 million and net loss widened to $4.8 million ($0.41/share). Nasdaq compliance was restored by meeting the minimum bid price requirement.
2. Phase 3 Results and NDA Filing
Positive Phase 3 trial outcomes for actinic keratosis on the extremities, neck and trunk supported a supplemental NDA submission. Management is preparing for an initial product rollout with its medical team in Q4, accelerating into Q1 2027 upon approval.
3. Operational Challenges and Outlook
Legal costs related to patent claims drove higher general and administrative expenses, and a going concern qualification underscores the need for additional capital. Uncertainty around FDA requirements for the acne vulgaris program may affect the timing and design of upcoming Phase 3 trials.